Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function

Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies sugges...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzini, Claudia, Venè, Roberta, Cossu, Irene, Gualco, Marina, Zupo, Simonetta, Dono, Mariella, Spagnolo, Francesco, Queirolo, Paola, Moretta, Lorenzo, Mingari, Maria Cristina, Pietra, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308621/
https://www.ncbi.nlm.nih.gov/pubmed/27563819
http://dx.doi.org/10.18632/oncotarget.11504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308621/
https://www.ncbi.nlm.nih.gov/pubmed/27563819
http://dx.doi.org/10.18632/oncotarget.11504

Ejemplares similares